Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Other Accumulated Expenses for 8 consecutive years, with $1.9 million as the latest value for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 28.41% to $1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Feb 2026, down 28.41% year-over-year, with the annual reading at $2.1 million for FY2025, 7.87% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $1.9 million at Nurix Therapeutics, down from $2.1 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $2.7 million in Q1 2025, with the low at $551000.0 in Q1 2022.
  • Average Other Accumulated Expenses over 5 years is $1.4 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses surged 272.71% in 2022, then plummeted 50.03% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $1.5 million in 2022, then tumbled by 50.03% to $751000.0 in 2023, then surged by 202.93% to $2.3 million in 2024, then fell by 7.87% to $2.1 million in 2025, then decreased by 8.16% to $1.9 million in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $1.9 million, $2.1 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.